HAVCR2 and neoplasm: This design leverages CMCS to protect gene drugs in physiological conditions, triggers synergistic drug release in the acidic microenvironment of the tumor, and significantly enhances the delivery efficiency of Tim‐3 siRNA and the anti‐angiogenesis effect of Sor to inhibit in situ LC progression.[455]